- Published on
Clinical Toxicology — Sotalol
1. Overview
Sotalol is an antiarrhythmic medication with two clinically important actions:
- Class II activity: Nonselective beta-adrenergic receptor blockade.
- Class III activity: Prolongation of cardiac repolarization through potassium-channel blockade.
Its combination of beta-blocking and QT-prolonging effects distinguishes sotalol from most other beta-blockers.
Sotalol poisoning can produce profound bradycardia, hypotension, atrioventricular block, QT prolongation, torsades de pointes, ventricular fibrillation, and cardiac arrest.
Serious toxicity can occur after overdose or during therapeutic treatment, particularly when kidney function deteriorates, electrolytes become abnormal, or another QT-prolonging medication is introduced.
The principal treatment goals are to maintain circulation, prevent and treat malignant ventricular dysrhythmias, correct electrolyte abnormalities, and consider hemodialysis in selected severe cases.
There is no single specific antidote.
2. Forms and therapeutic uses
Oral preparations
Sotalol is available in oral tablets, including 80 mg, 120 mg, 160 mg, and, for some products, 240 mg strengths.
Products include Betapace, Betapace AF, and generic sotalol formulations.
Ventricular arrhythmias
Sotalol is used to treat certain documented, life-threatening ventricular arrhythmias.
Its use does not eliminate the underlying risk of sudden cardiac death.
Atrial fibrillation and atrial flutter
Sotalol is also used to maintain sinus rhythm in selected patients with symptomatic atrial fibrillation or atrial flutter.
It is not routinely appropriate for every patient with atrial fibrillation because of its proarrhythmic potential.
Usual oral dosing
In adults with suitable kidney function, oral therapy commonly begins at 80 mg twice daily.
Doses may be increased according to clinical response, ECG findings, and renal function.
The dose and dosing interval must be individualized.
Intravenous sotalol
Modern intravenous sotalol is used for supervised initiation, dose escalation, or substitution for oral therapy.
The historical recommendation to administer intravenous sotalol over two to three minutes is obsolete.
Under current U.S. labeling:
- Intravenous loading doses are infused over approximately one hour.
- Intravenous doses used as substitutes for oral treatment are generally infused over five hours.
Exact intravenous doses depend on the indication, target oral regimen, kidney function, and product instructions.
Intravenous sotalol requires ECG monitoring and access to cardiac resuscitation.
3. Mechanism of action
Beta-adrenergic blockade
Sotalol blocks beta-1 and beta-2 adrenergic receptors.
Beta-1 blockade decreases sinus node activity, slows atrioventricular conduction, and reduces myocardial contractility.
Excessive beta blockade can cause bradycardia, atrioventricular block, hypotension, and cardiogenic shock.
Beta-2 blockade can produce bronchospasm and interfere with responses to hypoglycemia.
Potassium-channel blockade
Sotalol inhibits the rapid delayed rectifier potassium current, commonly designated IKr.
This prolongs ventricular action potential duration and repolarization.
On the ECG, the principal effect is QT prolongation.
Torsades de pointes
Prolonged repolarization facilitates early afterdepolarizations.
These may trigger a characteristic polymorphic ventricular tachycardia known as torsades de pointes.
Bradycardia as an additional risk
Sotalol’s QT-prolonging effects can become more pronounced at slower heart rates.
This phenomenon is called reverse use dependence.
Consequently, beta-blockade-induced bradycardia can amplify sotalol’s propensity to cause torsades.
Sotalol toxicity is therefore especially dangerous because its two pharmacologic actions can reinforce each other.
4. Pharmacokinetics
Absorption
Oral sotalol is well absorbed, with bioavailability exceeding approximately 90%.
Peak concentrations generally occur within two to four hours.
Food may modestly reduce absorption.
Distribution
Sotalol has relatively limited tissue distribution compared with highly lipophilic beta-blockers.
It has negligible plasma protein binding.
Metabolism
Sotalol is not substantially metabolized by the liver.
It does not depend on CYP450 metabolism for elimination.
Elimination
Most absorbed sotalol is eliminated unchanged by the kidneys.
Its usual elimination half-life is approximately 12 hours in adults with normal kidney function.
Renal impairment
As kidney function declines, sotalol clearance decreases.
The half-life may become markedly prolonged; values approaching 69 hours have been described in patients with anuria.
Clinical implications
Renal impairment increases the risk of drug accumulation, QT prolongation, and delayed or persistent toxicity.
Unlike many other beta-blockers, sotalol is sufficiently water-soluble, minimally protein-bound, and renally eliminated to be removed by hemodialysis.
5. Toxic dose
There is no reliable single toxic-dose threshold.
Serious adverse effects, including torsades de pointes, can occur at prescribed doses in susceptible patients.
Large overdose
The U.S. prescribing information describes severe poisonings involving approximately 2–16 g of sotalol.
Reported findings include bradycardia, hypotension, asystole, QT prolongation, torsades de pointes, and ventricular tachycardia.
Dose limitations
These case descriptions do not define a minimum lethal dose.
A smaller ingestion can be dangerous in patients with impaired kidney function, electrolyte abnormalities, preexisting cardiac disease, or interacting medications.
Accidental pediatric exposure
Even a limited number of adult-strength tablets may cause significant toxicity in a small child.
All potentially important pediatric exposures require prompt poison-center assessment.
Therapeutic accumulation
A patient taking a previously tolerated dose may become toxic if kidney function deteriorates or the prescribed dosing interval is no longer appropriate.
Toxicity does not require deliberate overdose.
6. Risk factors
Important risk factors include:
- Kidney impairment.
- Hypokalemia.
- Hypomagnesemia.
- Hypocalcemia.
- Bradycardia.
- Congenital long QT syndrome.
- Preexisting QT prolongation.
- Structural heart disease.
- Heart failure.
- Concurrent QT-prolonging medications.
- Excessive sotalol dosing.
- Inappropriate dosing intervals.
- Recent treatment initiation or dose escalation.
Sex-related risk
Women may have a higher risk of drug-induced torsades de pointes than men.
Age
Older patients are vulnerable when declining kidney function increases exposure.
Age itself is less important pharmacokinetically than associated reductions in renal clearance.
Clinical warning
Hypokalemia is a particularly important reversible risk factor for sotalol-associated torsades.
7. Drug and disease interactions
Other QT-prolonging medications
Examples include:
- Dofetilide.
- Ibutilide.
- Quinidine.
- Procainamide.
- Disopyramide.
- Certain antipsychotics.
- Certain macrolide and fluoroquinolone antibiotics.
- Selected antidepressants.
- Other medications known to prolong ventricular repolarization.
Such combinations can increase the risk of torsades.
Additional heart-rate-lowering drugs
Digoxin, verapamil, diltiazem, and other beta-blockers may increase the risk of bradycardia, heart block, or hypotension.
Electrolyte-depleting drugs
Diuretics or other agents that produce hypokalemia or hypomagnesemia can increase proarrhythmic risk.
Diabetes medications
Beta blockade can mask warning signs of hypoglycemia, particularly tachycardia.
Glucose monitoring may be necessary in susceptible patients.
Kidney disease
Sotalol requires dosing adjustment according to renal function.
Respiratory disease
Nonselective beta blockade may aggravate asthma or other bronchospastic conditions.
Important distinction
Drug interactions involving sotalol are driven primarily by cardiac electrophysiology, blood pressure, and kidney function, rather than CYP450 enzyme inhibition.
8. Clinical manifestations of acute poisoning
Cardiovascular findings
The most important manifestations include:
- Sinus bradycardia.
- Hypotension.
- Atrioventricular block.
- QT prolongation.
- Ventricular premature beats.
- Torsades de pointes.
- Ventricular fibrillation.
- Asystole.
Neurologic symptoms
Patients may experience dizziness, weakness, presyncope, syncope, confusion, or seizures.
Seizures can result from severe cerebral hypoperfusion during sustained dysrhythmias.
Respiratory findings
Bronchospasm may develop.
Respiratory failure can occur secondary to profound shock, altered consciousness, or cardiac arrest.
Metabolic findings
Hypoglycemia is possible, particularly in children.
Severe systemic illness may produce metabolic acidosis and other secondary abnormalities.
Cardiac failure
Profound beta blockade can impair cardiac output and produce acute heart failure or cardiogenic shock.
9. QT prolongation and torsades
Characteristic ECG pattern
The QT interval becomes prolonged because ventricular repolarization is delayed.
Marked prolongation increases the risk of torsades de pointes, particularly when accompanied by bradycardia.
Clinical warning threshold
Current U.S. labeling identifies QT of 500 milliseconds or greater as a threshold requiring dose reduction, prolongation of the dosing interval, or discontinuation during clinical therapy.
This is an important safety threshold, not an absolute dividing line between safe and dangerous overdose.
Torsades de pointes
Torsades is a potentially unstable polymorphic ventricular tachycardia associated with QT prolongation.
Episodes may terminate spontaneously or progress to ventricular fibrillation.
Repeated episodes may produce syncope, seizures, or cardiovascular collapse.
Pause-dependent torsades
The dysrhythmia may occur after a long pause or slow ventricular beat.
Bradycardia can therefore contribute directly to recurrence.
Clinical implication
Treatment must address both the prolonged QT interval and the slow heart rate.
10. Delayed toxicity
Most conventional beta-blocker overdoses produce symptoms relatively early.
Sotalol is an important exception.